Theravance Biopharma (NASDAQ:TBPH) vs. Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast

Theravance Biopharma (NASDAQ:TBPH) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings for Theravance Biopharma and Palisade Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	7	0	0	2.00
Palisade Bio	1	0	8	2	3.00

Theravance Biopharma presently has a consensus target price of $19.00, suggesting a potential upside of 11.57%. Palisade Bio has a consensus target price of $9.29, suggesting a potential upside of 700.49%. Given Palisade Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Theravance Biopharma.

Profitability

This table compares Theravance Biopharma and Palisade Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Palisade Bio	N/A	-33.47%	-31.79%

Institutional and Insider Ownership

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 7.6% of Theravance Biopharma shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Theravance Biopharma and Palisade Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31 million	8.48	$105.89 million	$1.01	16.86
Palisade Bio	$500,000.00	404.31	-$16.78 million	($0.48)	-2.42

Theravance Biopharma has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Theravance Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Summary

Theravance Biopharma beats Palisade Bio on 9 of the 15 factors compared between the two stocks.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.